Two supplement studies can look almost identical on paper and answer completely different questions. Which one you have, determines the claims you can make from it.
Take one bioavailability trial. 16 recreationally active adults. Single serving. Blood draws across an 8-hour window. One-week washout. Then repeat. A crossover study that effectively answers one question: do the nutrients show up in the blood after drinking it? And the answer was yes, the supplement significantly increased circulating levels of folate, calcium, zinc, vitamin C, biotin, and multiple B vitamins compared to placebo.
That is a clean result, and for a brand choosing between raw material forms it is exactly the right design.
If you already have absorption data, you are not starting over. It establishes that the formulation delivers, an assumption a status trial would otherwise carry on trust.
What absorption data does not tell you is whether nutritional status improved. Kinetics over eight hours and status over months are different outcomes, and the gap between them is not theoretical.
Now a second trial. Healthy men over 67 took a multivitamin and multi-mineral daily for six months. Vitamin status improved, with pyridoxal 5’-phosphate, calcifediol, alpha-tocopherol and beta-carotene rising while the placebo group drifted down (1)
So the question worth settling before you commission anything: which claim do you actually need?
Absorption. Single dose, small sample, short window. Fast and cheap. Answers “does it get in”.
Status. Likely 12 weeks minimum, repeated dosing, pre and post blood panels, powered for the biomarkers you care about. Answers “does it change the person”.
The two get treated as interchangeable in marketing claims, and that is where the exposure sits. Absorption data will not support a status claim if someone asks you to defend it.
Sequencing matters too. Run them in order, absorption first and status only once that publishes, and the evidence you actually need sits years out. Commission the status trial as the primary study and you are not waiting on the first one at all.
This is where decentralised design has its value. A 12 week status trial run remotely, with home phlebotomy and no site visits, recruits faster and costs less than a site-based equivalent.
Bioavailability proves the formulation works. Status proves the product does.
If you have a study in your pipeline, it is worth deciding which of the two you are buying.


